Table 4.

Exposure of JBD0131 and DM131 in Plasma of Beagle Dogs Following Oral Gavage Administration of JBD0131

Analyte	Dosing days	Sex	Dose (mg/kg)	n	AUC0–24 (h*ng/mL)		AUC0–96 (h*ng/mL)
					Mean	SD	Mean	SD
JBD0131	1	Female	15	5	5020	1600	/	/
			60	5	10,700	2800	/	/
			300	5	12,900	4950	/	/
		Male	15	4*	5570	1900	/	/
			60	5	13,900	4120	/	/
			300	5	20,000	4270	/	/
	28	Female	15	5	7340	2510	8530	3690
			60	4#	15,700	3840	24,800	9280
			300	5	19,400	5270	30,300	7150
		Male	15	5	6530	1930	7180	2820
			60	5	14,900	1520	20,100	3350
			300	5	22,200	4870	32,300	8390
DM131	1	Female	15	5	581	190	/	/
			60	5	550	107	/	/
			300	5	767	248	/	/
		Male	15	4*	630	192	/	/
			60	5	721	148	/	/
			300	5	1610	464	/	/
	28	Female	15	5	1190	363	1640	559
			60	4#	1720	656	3470	1680
			300	5	1850	489	3630	975
		Male	15	5	1090	363	1430	486
			60	5	1780	381	3100	977
			300	5	2270	694	4560	1620

^*Following the first dose, the plasma concentration of Dog No. 3M002 in the 15 mg/kg group was significantly lower than that of other animals in the same group; therefore, its TK parameters were excluded from the statistical analysis

^#Following the final dose, Dog No. 4F003 in the 60 mg/kg group vomited within 20 min after administration; therefore, its TK parameters were excluded from the statistical analysis